[go: up one dir, main page]

PE20081550A1 - Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos - Google Patents

Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos

Info

Publication number
PE20081550A1
PE20081550A1 PE2007000263A PE2007000263A PE20081550A1 PE 20081550 A1 PE20081550 A1 PE 20081550A1 PE 2007000263 A PE2007000263 A PE 2007000263A PE 2007000263 A PE2007000263 A PE 2007000263A PE 20081550 A1 PE20081550 A1 PE 20081550A1
Authority
PE
Peru
Prior art keywords
meridamycin
treatment
neurodegenerative disorders
analogs
alkyl
Prior art date
Application number
PE2007000263A
Other languages
English (en)
Inventor
Edmund Idris Graziani
Kevin Pong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20081550A1 publication Critical patent/PE20081550A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN DERIVADO DE MERIDAMICINA, DONDE R1 Y R2 SON OH, OXO, O(ALQUILO C1-C6), O(ACILO), ENTRE OTROS; R3, R4, R5 Y R6 SON OH, OXO, O(ALQUILO C1-C6), ENTRE OTROS; R3 Y R4 Y/O R5 Y R6 SE UNEN CONJUNTAMENTE PARA FORMAR UNA ESTRUCTURA -O-CXY-O- O R4 Y R5 SE UNEN PARA FORMAR -O-CXY-O-; X E Y SON H, ALQUILO C1-C6, ARILO, HETEROCICLILO, ENTRE OTROS; R7 ES CH2, CHOH O C=O; n ES 1 O 2. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS TALES COMO LA EPILEPSIA, ENFERMEDAD DE PARKINSON, ESCLEROSIS MULTIPLE, ENTRE OTROS
PE2007000263A 2006-03-07 2007-03-09 Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos PE20081550A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77994006P 2006-03-07 2006-03-07

Publications (1)

Publication Number Publication Date
PE20081550A1 true PE20081550A1 (es) 2008-12-31

Family

ID=38289934

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000263A PE20081550A1 (es) 2006-03-07 2007-03-09 Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos

Country Status (19)

Country Link
US (1) US7745457B2 (es)
EP (1) EP1991551A1 (es)
JP (1) JP2009529049A (es)
KR (1) KR20080099317A (es)
CN (1) CN101426796A (es)
AR (1) AR059738A1 (es)
AU (1) AU2007223962A1 (es)
BR (1) BRPI0708611A2 (es)
CA (1) CA2643350A1 (es)
CR (1) CR10272A (es)
EC (1) ECSP088718A (es)
IL (1) IL193414A0 (es)
MX (1) MX2008011312A (es)
NO (1) NO20083695L (es)
PE (1) PE20081550A1 (es)
RU (1) RU2008132779A (es)
TW (1) TW200804400A (es)
WO (1) WO2007103347A1 (es)
ZA (1) ZA200807678B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2005035605A (es) * 2004-12-20 2010-08-05 Wyeth Corp Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
BRPI0519593A2 (pt) * 2004-12-20 2009-02-25 Wyeth Corp composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) 1993-02-02 1993-03-17 Sandoz Ltd Compounds
GB9318144D0 (en) 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
WO1995014023A1 (en) 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US7247650B2 (en) * 2004-03-02 2007-07-24 Wyeth Macrolides and methods for producing same
CN1929837A (zh) * 2004-03-02 2007-03-14 惠氏公司 作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体
JP2008501342A (ja) * 2004-06-03 2008-01-24 ワイス 複合ポリケチドを生成するための生合成遺伝子クラスター
WO2006053313A2 (en) * 2004-11-12 2006-05-18 Wyeth Elaiophylin biosynthetic gene cluster
HN2005035605A (es) 2004-12-20 2010-08-05 Wyeth Corp Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
BRPI0519593A2 (pt) 2004-12-20 2009-02-25 Wyeth Corp composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto

Also Published As

Publication number Publication date
CN101426796A (zh) 2009-05-06
BRPI0708611A2 (pt) 2011-06-07
US7745457B2 (en) 2010-06-29
RU2008132779A (ru) 2010-04-20
AR059738A1 (es) 2008-04-23
NO20083695L (no) 2008-10-03
US20070213525A1 (en) 2007-09-13
AU2007223962A1 (en) 2007-09-13
JP2009529049A (ja) 2009-08-13
EP1991551A1 (en) 2008-11-19
ECSP088718A (es) 2008-10-31
CR10272A (es) 2008-10-03
CA2643350A1 (en) 2007-09-13
MX2008011312A (es) 2008-09-12
KR20080099317A (ko) 2008-11-12
ZA200807678B (en) 2009-08-26
IL193414A0 (en) 2009-05-04
TW200804400A (en) 2008-01-16
WO2007103347A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
CL2011002838A1 (es) Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos de receptores mglur2; composición farmacéutica; proceso para prepararla; y su uso en el tratamiento o la prevención de un trastorno del sistema nervioso central seleccionado de ansiedad y esquizofrenia, entre otros.
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
EA201270012A1 (ru) Сублингвальный апоморфин
DOP2005000040A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
CL2011003302A1 (es) Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros.
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
AR065622A1 (es) Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
AR068510A1 (es) Derivados de 4-fenil-1h-piridin-2-ona - 1,3 disustituidos, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir trastornos del sistema nervioso central.
CL2008002745A1 (es) Compuestos derivados de 1`, 3`-disustituidos-4-fenil-3,4,5,6-tetrahidro-2h- 1`h[1,4`]bipiridinil-2`-ona, modulares alostericos positivos del receptor glutamatergico mglur2; composicion farmaceutica; y uso de los compuestos en el tratamiento del sistema nervioso central mediado por mglur2.
GT200300219A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
CL2011002839A1 (es) Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos positivos de receptores mglur2; composición farmacéutica y su proceso de preparacion; combinación farmaceutica; y su uso en el tratamiento o prevencion de un trastorno del sistema nervioso central tal como ansiedad y esquizofrenia, entre otros.
CL2009000699A1 (es) Compuestos derivados de 6-heteroaril-imidazo[1,2-a]piridinas polisustituidas; composicion farmaceutica; procedimiento de sintesis; compuestos intermediarios; y su uso para tratar o prevenir enfermedades neurodegenerativas, psiquiatricas, inflamatorias, traumatismos cerebrales y de la epilepsia, osteoporosis, cancer, parkinson, entre otras.
GT200500368A (es) Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
ECSP077275A (es) Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos
CL2009000990A1 (es) Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
PH12012501853A1 (en) Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
GT200700103A (es) Compuestos biciclocarboxiamida sustituidos
ECSP15015155A (es) Moduladores de quinolinilo unidos a fenilo de ror–gamma–t
BR112012022910A2 (pt) inibidores de pde10 e composições e métodos relacionados
TW201144306A (en) Bicyclic heteroaryl analogues as GPR119 modulators
GT200500297A (es) Sintesis asimetrica de dehidrobenzofuranos sustituidos
AR072265A1 (es) Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende
BR112012022255A2 (pt) composição farmaceuticaestabilizada
PE20081550A1 (es) Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos

Legal Events

Date Code Title Description
FX Voluntary withdrawal